The European Leukodystrophy Association announces the launch of a clinical trial for adult patients suffering from adrenomyeloneuropathy.
Thanks to the generosity of their donors, the ELA have allocated 800,000 Euros to completely fund a new clinical trial to evaluate the effects of a new molecule on patients suffering from adrenomyeloneuropathy (AMN).
Dr Frederic Sedel’s research work to which ELA contributed led to the identification of the MD1003 molecule as a promising treatment for progressive multiple sclerosis. Certain preliminary results on adrenomyeloneuropathy (AMN) paved the way for a new clinical trial testing the effects of MD1003 on AMN which will soon be starting.
For more information visit Clinical Trial for Adult AMN Patients